Patents by Inventor Margaret Mary Faul

Margaret Mary Faul has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline 2,5-dione-3-(1-methyl-1H-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl]-1H-pyrrole mono-hydrochloride
    Patent number: 8114901
    Abstract: The present invention relates to crystalline 2,5-dione-3-(1-methyl-1H-indol-3-yl)-4-[1-(pyridin-2-yl-methyl)piperidin-4-yl]-1H-indol-3-yl]-1H-pyrrole mono-hydrochloride salt, a pharmaceutical formulation containing said salt and to methods for treating cancer and for inhibiting tumor growth using said salt.
    Type: Grant
    Filed: July 8, 2003
    Date of Patent: February 14, 2012
    Assignee: Eli Lilly and Company
    Inventors: Julie Kay Bush, Margaret Mary Faul, Susan Marie Reutzel-Edens
  • Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders
    Patent number: 7214673
    Abstract: Described herein are antipyschotic compounds of formula (I) wherein, A is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, O, and S; Alk is (C1-4) alkylene optionally substituted with OH, methoxy, ethoxy, or F; Ar is optionally substituted phenyl, naphthyl, monocyclic heteroaromatic, or bicyclic heteroaromatic; R1 is hydrogen or (C1-4) alkyl optionally substituted with OH, OR3, or OCH2CH2OH, wherein R3 is (C1-2) alkyl; R2 is H, (C1-6) alkyl, halogen, fluorinated (C1-6) alkyl, OR4, SR4, NO2, CN, COR4, CONR5R6, SO2NR5R6, NR5R6, NR5COR4, NR5SO2R4, or optionally substituted phenyl, wherein R4 is hydrogen, (C1-6) alkyl, fluorinated (C1-6) alkyl, or optionally substituted phenyl, R5 and R6 are independently hydrogen, (C1-6) alkyl, or optionally substituted phenyl; Z is one or two substituents independently selected from hydrogen, halogen, (C1-6) alkyl, fluorinated (C1-6) alkyl, OR7, SR7, NO2, CN, COR7, CONR8R9, SO2NR8R9, NR8SO2R
    Type: Grant
    Filed: March 17, 2003
    Date of Patent: May 8, 2007
    Assignee: Eli Lilly and Company
    Inventors: Thomas Daniel Aicher, Zhaogen Chen, Joseph Herman Krushinski, Jr., Yvan Le Huerou, Marta Maria Pineiro-Nunez, Kevin Michael Ruley, John Mehnert Schaus, Dennis Charles Thompson, David Edward Tupper, Ying Chen, Margaret Mary Faul, Vincent Patrick Rocco
  • Hypoglycemic and hypolipidemic compounds
    Patent number: 6541497
    Abstract: This invention provides compounds and their pharmaceutically-acceptable salts, pharmaceutical formulations of said compounds, and methods for treating hyperglycemia associated with non-insulin dependent diabetes and for treating hyperlipidemia.
    Type: Grant
    Filed: March 3, 2000
    Date of Patent: April 1, 2003
    Assignee: Eli Lilly and Company
    Inventors: Samuel James Dominianni, Margaret Mary Faul, Russell Dean Stucky, Leonard Larry Winneroski, Jr.
  • Hypoglycemic and hypolipidemic compounds
    Patent number: 6353027
    Abstract: This invention provides compounds and their pharmaceutically-acceptable salts, pharmaceutical formulations of said compounds, and methods for treating hyperglycemia associated with non-insulin dependent diabetes and for treating hyperlipidemia.
    Type: Grant
    Filed: March 3, 2000
    Date of Patent: March 5, 2002
    Assignee: Eli Lilly and Company
    Inventors: Samuel James Dominianni, Margaret Mary Faul, Russell Dean Stucky, Leonard Larry Winneroski, Jr.
  • Hypoglycemic and hypolipidemic compounds
    Patent number: 6194446
    Abstract: This invention provides compounds and their pharmaceutically-acceptable salts, pharmaceutical formulations of said compounds, and methods for treating hyperglycemia associated with non-insulin dependent diabetes and for treating hyperlipidemia.
    Type: Grant
    Filed: December 18, 1998
    Date of Patent: February 27, 2001
    Assignee: Eli Lilly and Company
    Inventors: Samuel James Dominianni, Margaret Mary Faul, Russell Dean Stucky, Leonard Larry Winneroski, Jr.
  • Synthesis of bisindolylmalimides
    Patent number: 6133452
    Abstract: The present invention provides for the reaction of optionally substituted indole-3-acetamides with optionally substituted methyl indole-3-glyoxyl reagent to prepare potent PKC inhibitors. The reaction is very efficient and robust macrocyclization methodology.
    Type: Grant
    Filed: January 21, 1999
    Date of Patent: October 17, 2000
    Assignee: Eli Lilly and Company
    Inventors: Margaret Mary Faul, Leonard Larry Winneroski, Jr.
  • Protein kinase C inhibitor
    Patent number: 6117861
    Abstract: This invention provides novel bis-indolylmaleimide macrocycle derivatives of the formula: ##STR1## and solvates thereof. The invention further provides the preparation, pharmaceutical formulations and the methods of use for inhibiting Protein Kinase C in mammals.
    Type: Grant
    Filed: December 7, 1999
    Date of Patent: September 12, 2000
    Assignee: Eli Lilly and Company
    Inventors: Gary Lowell Engel, Nagy Alphonse Farid, Margaret Mary Faul, Michael Robert Jirousek, Lori Ann Richardson, Leonard Larry Winneroski, Jr.
  • Protein kinase C inhibitor
    Patent number: 6015807
    Abstract: This invention provides novel bis-indolylmaleimide macrocycle derivatives of the formula: and solvates thereof. The invention further provides the preparation, pharmaceutical formulations and the methods of use for inhibiting Protein Kinase C in mammals.
    Type: Grant
    Filed: November 7, 1997
    Date of Patent: January 18, 2000
    Assignee: Eli Lilly and Company
    Inventors: Gary Lowell Engel, Nagy Alphonse Farid, Margaret Mary Faul, Michael Robert Jirousek, Lori Ann Richardson, Leonard Larry Winneroski, Jr.
  • Synthesis of bisindolylmaleimides
    Patent number: 5990319
    Abstract: The present invention provides for the reaction of optionally substituted indole-3-acetamides with optionally substituted methyl indole-3-glyoxyl reagent to prepare potent PKC inhibitors. The reaction is a very efficient and robust macrocyclization methodology.
    Type: Grant
    Filed: August 22, 1997
    Date of Patent: November 23, 1999
    Assignee: Eli Lilly and Company
    Inventors: Margaret Mary Faul, Leonard Larry Winneroski, Jr.
  • Synthesis of bisindolylmaleimides
    Patent number: 5948907
    Abstract: The present invention provides for the reaction of optionally substituted indole-3-acetamides with optionally substituted methyl indole-3-glyoxyl reagent to prepare potent PKC inhibitors.
    Type: Grant
    Filed: May 19, 1998
    Date of Patent: September 7, 1999
    Assignee: Eli Lilly and Company
    Inventors: Margaret Mary Faul, Leonard Larry Winneroski, Jr.
  • Intermediates and their use to prepare N,N'-bridged bisindolylmaleimides
    Patent number: 5721272
    Abstract: This invention provides compounds of the formula: ##STR1## The invention further provides the use of this compound to prepare N,N'-bridged bisindolylmaleimides. Furthermore, the invention provides pharmaceutical formulations and the methods of use for inhibiting Protein Kinase C in mammals.
    Type: Grant
    Filed: November 18, 1996
    Date of Patent: February 24, 1998
    Assignee: Eli Lilly and Company
    Inventors: Margaret Mary Faul, Christine Ann Krumrich, Leonard Larry Winneroski, Jr.
  • Protein kinase C inhibitor
    Patent number: 5710145
    Abstract: This invention provides novel bis-indolylmaleimide macrocycle derivatives of the formula: ##STR1## and solvates thereof. The invention further provides the preparation, pharmaceutical formulations and the methods of use for inhibiting Protein Kinase C in mammals.
    Type: Grant
    Filed: November 18, 1996
    Date of Patent: January 20, 1998
    Assignee: Eli Lilly and Company
    Inventors: Gary Lowell Engel, Nagy Alphonse Farid, Margaret Mary Faul, Michael Robert Jirousek, Lori Ann Richardson, Leonard Larry Winneroski, Jr.